CClinicalTrials.gg
Status unknownNCT04961879Updated Feb 17, 2022

Dorsal Finger Reconstruction

An interventional study of Reversed Cross Finger Flap and reversed island homo-digital flap in Finger Injuries, sponsored by Sohag University. Status unknown at 1 site in Egypt. Open to participants aged 5 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-02-17.

Sponsored by Sohag University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2022), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
5 Years to 70 Years
Sex
All
01

Study summary

objective of this study is To compare reversed cross finger flap with reversed island homo-digital flap in distal dorsal finger defect reconstruction regarding reliability \& functional and aesthetic outcomes .

comparative study that will be conducted at Plastic surgery department, Sohag university hospital on 30 patients .The population of the study will be patients with distal dorsal digital defects. We will divide the cases into two equal groups: the first are operated with reversed cross-finger flap and the second are operated with reversed island homo-digital flap.

02

Conditions studied

  • Finger Injuries

Browse trials for

03

In context

Finger Injuries

23 studies on the registry are indexed under Finger Injuries; 3 are open to participants now.

This study's planned enrollment of 30 is below the median of 60 across 18 interventional studies indexed under Finger Injuries.

Browse Finger Injuries studies →

Lead sponsor

Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • patients with dorsal digital defect distal to distal interphalangeal joint (DIP) joint
  • defect size ranged from 1 to 2 cm in width and 1-3 cm in length

Exclusion criteria

Exclusion Criteria:

  • chronic heavy smokers,
  • traumatic injury to the donor site and perforator .
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Reversed Cross Finger Flap group 1

    Procedure: Reversed Cross Finger Flap

  • Active comparator
    Reversed island Homo-digital Flap group 2

    Procedure: reversed island homo-digital flap

Interventions

  • ProcedureReversed Cross Finger Flap

    distal dorsal finger defect will be reconstructed by reversed cross finger flap - reversed cross finger flap is a modified cross finger flap harvested from an adjacent finger .

  • Procedurereversed island homo-digital flap

    distal dorsal finger defect will be reconstructed by reversed island homo-digital flap - this flap is harvested from the same finger .

06

What researchers measure

Primary outcomes

  1. difference in range of motion between group 1 and group 2

    difference in range of motion between group 1 and group 2 will be measured by manual goniometer in degrees

    Time frame: difference in range of motion between group 1 and group 2 will be measured at 4 months postoperative

07

Study locations

1 site
  • Sohag University
    Sohag, 82525, Egypt
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04961879
Lead sponsor
Sohag University
Responsible party
Elhossieny abdelaal mohamed (Principal Investigator, Sohag University) — Principal investigator
First posted
Jul 14, 2021
Start date
Jul 14, 2021
Primary completion
Feb 2022 (estimated)
Completion
Mar 2022 (estimated)
Last update
Feb 17, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion